BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 6305033)

  • 21. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival.
    Cance WG; Carey LA; Calvo BF; Sartor C; Sawyer L; Moore DT; Rosenman J; Ollila DW; Graham M
    Ann Surg; 2002 Sep; 236(3):295-302; discussion 302-3. PubMed ID: 12192316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Salvage treatment for local recurrence after breast-conserving surgery and radiation as initial treatment for mammographically detected ductal carcinoma in situ of the breast.
    Solin LJ; Fourquet A; Vicini FA; Haffty B; Taylor M; McCormick B; McNeese M; Pierce LJ; Landmann C; Olivotto IA; Borger J; de La Rochefordiere A; Schultz DJ
    Cancer; 2001 Mar; 91(6):1090-7. PubMed ID: 11267953
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Local recurrence rates in breast cancer patients treated with intraoperative electron-boost radiotherapy versus postoperative external-beam electron-boost irradiation. A sequential intervention study.
    Reitsamer R; Peintinger F; Kopp M; Menzel C; Kogelnik HD; Sedlmayer F
    Strahlenther Onkol; 2004 Jan; 180(1):38-44. PubMed ID: 14704843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Breast lobular carcinoma in situ: diagnosis and evolution].
    Espié M; Hocini H; Cuvier C; Giacchetti S; Bourstyn E; de Roquancourt A
    Gynecol Obstet Fertil; 2005 Dec; 33(12):964-9. PubMed ID: 16324870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Relation between dysplasias, benign breast tumors and cancer of the breast. Retrospective study in a group of 735 patients].
    Badellino F; Santoro L; Volterrani P; Trabucco A; Tardy A
    Cancro; 1974; 27(5):263-70. PubMed ID: 4376974
    [No Abstract]   [Full Text] [Related]  

  • 26. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection.
    Schulze T; Mucke J; Markwardt J; Schlag PM; Bembenek A
    J Surg Oncol; 2006 Feb; 93(2):109-19. PubMed ID: 16425290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence and kinetics of distant metastases in patients with operable breast cancer.
    Kryj M; Maciejewski B; Withers HR; Taylor JM
    Neoplasma; 1997; 44(1):3-11. PubMed ID: 9201274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognosis after regional lymph node recurrence in patients with stage I-II breast carcinoma treated with breast conservation therapy.
    Harris EE; Hwang WT; Seyednejad F; Solin LJ
    Cancer; 2003 Nov; 98(10):2144-51. PubMed ID: 14601083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors predicting in-breast tumor recurrence after breast-conserving surgery.
    Mechera R; Viehl CT; Oertli D
    Breast Cancer Res Treat; 2009 Jul; 116(1):171-7. PubMed ID: 18815880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome.
    Mazouni C; Peintinger F; Wan-Kau S; Andre F; Gonzalez-Angulo AM; Symmans WF; Meric-Bernstam F; Valero V; Hortobagyi GN; Pusztai L
    J Clin Oncol; 2007 Jul; 25(19):2650-5. PubMed ID: 17602071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lobular neoplasia. Long term risk of breast cancer and relation to other factors.
    Bodian CA; Perzin KH; Lattes R
    Cancer; 1996 Sep; 78(5):1024-34. PubMed ID: 8780540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [In situ carcinomas of the breast: clinical features and therapeutic strategies].
    Attene F; Scognamillo F; Trignano E; Meloni GB; Rubino C; Trignano M
    Ann Ital Chir; 2006; 77(1):3-10; discussion 10-2. PubMed ID: 16910353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimal management of ductal carcinoma in situ of the breast.
    Sakorafas GH; Farley DR
    Surg Oncol; 2003 Dec; 12(4):221-40. PubMed ID: 14998563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer of the second breast.
    Donegan WL; Spratt JS
    Major Probl Clin Surg; 1979; 5():464-83. PubMed ID: 222971
    [No Abstract]   [Full Text] [Related]  

  • 35. Risk of subsequent invasive breast cancer after breast carcinoma in situ.
    Wärnberg F; Yuen J; Holmberg L
    Lancet; 2000 Feb; 355(9205):724-5. PubMed ID: 10703809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Consensus Conference on the treatment of in situ ductal carcinoma of the breast, April 22-25, 1999.
    Schwartz GF; Solin LJ; Olivotto IA; Ernster VL; Pressman PI
    Hum Pathol; 2000 Feb; 31(2):131-9. PubMed ID: 10685626
    [No Abstract]   [Full Text] [Related]  

  • 37. Geometry, growth rates, and duration of cancer and carcinoma in situ of the breast before detection by screening.
    Spratt JS; Greenberg RA; Heuser LS
    Cancer Res; 1986 Feb; 46(2):970-4. PubMed ID: 3940657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The diagnosis and management of pre-invasive breast disease--current challenges, future hopes.
    Lakhani SR
    Breast Cancer Res; 2003; 5(5):248-9. PubMed ID: 12927033
    [No Abstract]   [Full Text] [Related]  

  • 39. Diagnostic drift in the reporting of cancer incidence.
    Bailar JC
    J Natl Cancer Inst; 1998 Jun; 90(11):863-4. PubMed ID: 9625178
    [No Abstract]   [Full Text] [Related]  

  • 40. Mitigating overdiagnosis and overtreatment in breast cancer: what is the role of the pathologist?
    Calhoun BC; Livasy CA
    Arch Pathol Lab Med; 2014 Nov; 138(11):1428-31. PubMed ID: 24628451
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.